|Venture Round, 10/2010 ||$727k|
|Partial Close, 6/2013 ||$2.27M|
|Debt, 3/2011 ||$497k|
|Debt, 3/2014 ||$170k|
Arrogene, Inc., a development stage company, engages in developing nano-biopolymers and related technologies cancer therapeutics and diagnostics in the United States. Its products include nanopolymer Polycefin that is in pre-clinical development to block Laminin-411 production in primary and metastatic brain and breast tumors; Laminin-411, a diagnostic tool for advanced brain glioma and as a prognostic indicator that predicts disease recurrence; and Laminin-421. The company was founded in 2007 and is based in Santa Monica, California.